GlassScriptPhysician profile
Chao-I Lin
NPI 1588779631
$14,035.79
in general payments reported to CMS, 2019-2025
30 companies · $1,995 in 2025
The $1,995 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,207 · 2020: $1,362 · 2021: $1,851 · 2022: $1,939 · 2023: $2,553 · 2024: $2,129 · 2025: $1,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,606 · Education: $71.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,605.79 |
| Education | $71.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,095.50 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,666.94 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Pfizer INC. | $1,281.80 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,174.89 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $978.65 | 2019-2025 | Dupixent |
| Genzyme Corporation | $812.75 | 2019-2025 | |
| Leo Pharma INC. | $740.29 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $665.76 | 2019-2025 | |
| Amgen INC. | $649.46 | 2021-2025 | Tezspire |
| Csl Behring | $616.55 | 2019-2025 | Hizentra, Haegarda |
| Optinose US, INC. | $608.46 | 2019-2025 | |
| Grifols USA, LLC | $428.49 | 2020-2025 | Xembify |
| Genentech USA, INC. | $368.79 | 2021-2025 | Xolair |
| Pharming Healthcare, INC. | $349.22 | 2019-2024 | Ruconest |
| Biocryst US Sales Co., LLC | $325.31 | 2021-2025 | Orladeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $260.88 | 2021-2023 | Opzelura |
| Teva Pharmaceuticals USA, INC. | $244.32 | 2019-2021 | |
| Alk-Abello, INC | $214.39 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Kaleo, INC. | $112.49 | 2019-2024 | Auvi-Q |
| Shire North American Group INC | $111.43 | 2019 | |
| Octapharma USA, INC. | $66.45 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $57.63 | 2025 | Neffy |
| Cycle Pharmaceuticals INC | $50.71 | 2025 | Sajazir |
| Blueprint Medicines Corporation | $29.91 | 2024 | Ayvakit |
| Biocryst Pharmaceuticals, INC. | $29.87 | 2020 | |
| Abbvie INC. | $29.14 | 2024 | |
| Adma Biomanufacturing LLC | $22.62 | 2021 | |
| Ionis Pharmaceuticals, INC. | $15.18 | 2025 | Dawnzera |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 | |
| Uswm, LLC | $13.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chao-I Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.